MX2013001583A - Agente profilactico para esteatohepatitis no alcoholica. - Google Patents

Agente profilactico para esteatohepatitis no alcoholica.

Info

Publication number
MX2013001583A
MX2013001583A MX2013001583A MX2013001583A MX2013001583A MX 2013001583 A MX2013001583 A MX 2013001583A MX 2013001583 A MX2013001583 A MX 2013001583A MX 2013001583 A MX2013001583 A MX 2013001583A MX 2013001583 A MX2013001583 A MX 2013001583A
Authority
MX
Mexico
Prior art keywords
fatty liver
liver
ibudilast
nash
fatty
Prior art date
Application number
MX2013001583A
Other languages
English (en)
Spanish (es)
Inventor
Toshiyuki Matsui
Tomohiro Ide
Masaki Tsunoda
Tomomi Ogata
Minoru Ito
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX2013001583A publication Critical patent/MX2013001583A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2013001583A 2010-08-12 2011-08-11 Agente profilactico para esteatohepatitis no alcoholica. MX2013001583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010180656 2010-08-12
PCT/JP2011/068344 WO2012020821A1 (ja) 2010-08-12 2011-08-11 非アルコール性脂肪肝炎の予防または治療剤

Publications (1)

Publication Number Publication Date
MX2013001583A true MX2013001583A (es) 2013-03-21

Family

ID=45567781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001583A MX2013001583A (es) 2010-08-12 2011-08-11 Agente profilactico para esteatohepatitis no alcoholica.

Country Status (11)

Country Link
US (1) US20130143913A1 (zh)
EP (1) EP2604607A4 (zh)
JP (1) JPWO2012020821A1 (zh)
KR (1) KR20130097722A (zh)
CN (1) CN103189374A (zh)
BR (1) BR112013003064A2 (zh)
CA (1) CA2808039A1 (zh)
MX (1) MX2013001583A (zh)
RU (1) RU2013110517A (zh)
TW (1) TW201211041A (zh)
WO (1) WO2012020821A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
CN105039513B (zh) * 2015-05-29 2018-12-28 广州市第一人民医院 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
AU2017356947A1 (en) * 2016-11-08 2019-05-30 University Of Louisville Research Foundation, Inc. Encapsulation of phosphodiesterase inhibitors to treat alcoholic liver disease
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1570847B1 (en) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP5443012B2 (ja) 2009-02-09 2014-03-19 タキロン株式会社 排水管路構造及びこれに用いる管継手

Also Published As

Publication number Publication date
CA2808039A1 (en) 2012-02-16
WO2012020821A1 (ja) 2012-02-16
BR112013003064A2 (pt) 2018-01-30
CN103189374A (zh) 2013-07-03
KR20130097722A (ko) 2013-09-03
US20130143913A1 (en) 2013-06-06
EP2604607A4 (en) 2014-01-01
RU2013110517A (ru) 2014-09-20
EP2604607A1 (en) 2013-06-19
JPWO2012020821A1 (ja) 2013-10-28
TW201211041A (en) 2012-03-16

Similar Documents

Publication Publication Date Title
Wang et al. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases
Naidu et al. Ameliorative potential of gingerol: Promising modulation of inflammatory factors and lipid marker enzymes expressions in HFD induced obesity in rats
CN110200981A (zh) 五环三萜皂苷的医药用途及其药物组合物
Angulo et al. Treatment of non-alcoholic steatohepatitis
TW201733582A (zh) Fxr促效劑及arb之組合醫藥
Raja et al. Clozapine safety, 40 years later
MX2013001583A (es) Agente profilactico para esteatohepatitis no alcoholica.
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
KR102271821B1 (ko) 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물
CN110876751B (zh) 曲美替尼在制备预防和/或治疗非酒精性肝炎和/或非酒精性脂肪性肝病中的应用
Morita et al. Chronic hyperinsulinemia contributes to insulin resistance under dietary restriction in association with altered lipid metabolism in Zucker diabetic fatty rats
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
WO2019227764A1 (zh) 一种mln4924在制备治疗糖尿病和/或肥胖药物的新用途
KR20130113921A (ko) 비알코올성 지방성 간염의 예방 및/또는 치료제
KR20210031884A (ko) 아젤라산을 유효성분으로 포함하는 지방간 예방, 치료, 또는 개선용 조성물
Pongkorpsakol et al. Fatty acid and mineral receptors as drug targets for gastrointestinal disorders
CN112823007A (zh) 用巴瑞替尼治疗原发性胆汁性胆管炎和原发性硬化性胆管炎
Bavuu et al. Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet
CN105878225B (zh) 氨基乙酰丙酸在脂肪肝治疗中的应用
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
Huang et al. Ophiopogonin D ameliorates non‑alcoholic fatty liver disease in high‑fat diet‑induced obese mice by improving lipid metabolism, oxidative stress and inflammatory response
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
US20230346803A1 (en) Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
KR20230067992A (ko) 지방간 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
FA Abandonment or withdrawal